Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi‐institutional retrospective cohort study

To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy.

[1]  Katie S. Murray,et al.  Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience , 2022, The Journal of urology.

[2]  M. Schoenberg,et al.  Complications Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma. , 2020, Urology.

[3]  F. Petros.  Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma , 2020, Translational andrology and urology.

[4]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[5]  P. Pierorazio,et al.  Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives. , 2020, Urology.

[6]  D. Lifshitz,et al.  Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. , 2020, The Lancet. Oncology.

[7]  F. Regis,et al.  Adjuvant single-dose upper urinary tract instillation of mitomycin C after therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial. , 2020, Journal of endourology.

[8]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[9]  Bryan M. Krause,et al.  Association between major surgical admissions and the cognitive trajectory: 19 year follow-up of Whitehall II cohort study , 2019, BMJ.

[10]  Ashleigh E. Smith,et al.  Cognitive outcomes following coronary artery bypass grafting: A systematic review and meta-analysis of 91,829 patients , 2019, International journal of cardiology.

[11]  J. Ioannidis,et al.  Hypnotic depth and postoperative death: a Bayesian perspective and an Independent Discussion of a clinical trial. , 2019, British journal of anaesthesia.

[12]  B. Silbert,et al.  Postoperative Cognitive Dysfunction and Noncardiac Surgery , 2018, Anesthesia and analgesia.

[13]  D. Canes,et al.  An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database , 2018, Clinical genitourinary cancer.

[14]  V. Margulis,et al.  Therapeutic strategies for upper tract urothelial carcinoma , 2018, Expert review of anticancer therapy.

[15]  S. Matin,et al.  Endoscopic Approaches to Upper Tract Urothelial Carcinoma. , 2018, The Urologic clinics of North America.

[16]  Yanfei Xia,et al.  The correlation of the depth of anesthesia and postoperative cognitive impairment: A meta-analysis based on randomized controlled trials. , 2018, Journal of clinical anesthesia.

[17]  M. Babjuk,et al.  Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. , 2016, European urology.

[18]  F. Montorsi,et al.  Early repeated ureteroscopy within 6–8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings , 2016, World Journal of Urology.

[19]  J. Raman,et al.  Critical analysis of 30 day complications following radical nephroureterectomy for upper tract urothelial carcinoma. , 2014, The Canadian journal of urology.

[20]  K. Bensalah,et al.  High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. , 2014, Urologic oncology.

[21]  M. Grasso,et al.  Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15‐year comprehensive review of 160 consecutive patients , 2012, BJU international.

[22]  T. Kessler,et al.  Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? , 2011, European urology.

[23]  S. Shariat,et al.  Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma , 2011, World Journal of Urology.

[24]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[25]  S. Chueh,et al.  CONSERVATIVE MANAGEMENT IN SELECTED PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA COMPARES FAVOURABLY WITH EARLY RADICAL SURGERY , 2008, BJU international.